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Abstract 
Non-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism 
in patients with atrial fibrillation (AF). There has been no head-to-head comparison of the 
effect of these agents on ex-vivo thrombotic and thrombolytic status. Enhanced platelet 
reactivity and impaired endogenous thrombolysis are risk factors for recurrent thrombotic 
events. We aimed to assess the comparative effect of NOACs and warfarin using an ex-vivo 
test of thrombosis and thrombolysis. Eighty patients with newly diagnosed non-valvular AF 
were tested before, and after being established on apixaban (n=20), dabigatran (n=20), 
rivaroxaban (n=20), or warfarin (n=20). Thrombotic status was assessed with the automated, 
point-of-care Global Thrombosis Test (GTT), that assesses both platelet reactivity and 
endogenous thrombolysis from native blood. The time taken to form an occlusive thrombus 
(occlusion time, OT), and the time required to restore flow through endogenous thrombolysis 
(lysis time, LT) were measured. All anticoagulants caused OT prolongation compared to 
baseline (apixaban 403±102s vs. 496±125s, p=0.006; dabigatran 471±106s vs. 656±165s, 
p<0.00001; rivaroxaban 381±119s vs. 579±158, p<0.00001; warfarin 420±145s vs. 604±124s, 
p<0.00001). Apixaban reduced LT from baseline (1895[1702-2167]s vs. 1435[347-1990]s; 
p=0.006). A trend for LT reduction was seen with other NOACs (dabigatran 1594[1226-2069]s 
vs. 1539[561-2316]s, p=0.499; rivaroxaban 2085[1366-2428]s vs. 1885[724-2420]s, p=0.295) 
but not warfarin (1490[1206-1960]s vs. 1776[1545-2334], p=0.601). Our results suggest that 
NOACs and warfarin have a similar favourable effect on reducing platelet reactivity. All NOACs 
exhibited a trend towards enhancing endogenous thrombolytic status, although this was 
significant only for apixaban. This raises the possibility of using NOACs to enhance impaired 
endogenous fibrinolysis in patients at high thrombotic risk.	
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GTT = Global Thrombosis Test 
LT = lysis time 
NVAF = non-valvular atrial fibrillation 
NOACs = non-vitamin K antagonist oral anticoagulants 
OT = occlusion time 
PFTs = platelet function tests 
VKAs = vitamin K antagonists 
 
  
 
 
5 
 
Background 
Non-vitamin K antagonist oral anticoagulants (NOACs) are licensed for the 
thromboprophylaxis of stroke and systemic embolism in patients with non-valvular atrial 
fibrillation (NVAF) and are non-inferior to warfarin [1-4] 1-4. There has been no head-to-head 
comparison of the effect of these agents on ex vivo thrombotic and thrombolytic status. 
Enhanced platelet reactivity and impaired endogenous thrombolysis are risk factors for 
recurrent thrombotic events [5,6] 5,6. The rate of major bleeding associated with NOACs 
compared to warfarin is variable. Apixaban demonstrated a significantly lower rate of major 
bleeding compared to warfarin [7] 7, whereas dabigatran at the 150 mg BID dose and 
rivaroxaban were similar to warfarin in RELY [4] 4 and Rocket AF [8] 8, although subsequent 
registries suggest that major bleeding is infrequent with rivaroxaban [9,10] 9,10. NOACs reduce 
the occurrence of intracranial bleeding significantly compared to warfarin. However, there 
has been concern that dabigatran, particularly at high dose, is associated with more 
gastrointestinal bleeding [11,12] 11,12.  
All NOACs exert their anticoagulant effects through direct or indirect thrombin inhibition. 
Data suggest that NOACs do not affect platelet reactivity to common agonists (ADP, 
arachidonic acid, collagen) [13-15] 13-15, and their effect on platelets may be confined to 
inhibiting α-thrombin-induced platelet aggregation. Even the latter is controversial, as 
dabigatran, but not rivaroxaban, enhanced thrombin receptor activating peptide (TRAP)-
induced platelet aggregation as measured by multiple electrode aggregometry [16] 16. 
However, conventional point-of-care platelet function tests (PFTs) cannot be used to monitor 
NOACs, since these tests measure platelet reactivity to various soluble platelet agonists and 
neither NOACs nor warfarin have an effect on this [13,14] 13,14. Further, as these tests use 
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citrate-anticoagulated blood, thrombin is not generated from activated platelets and the 
important procoagulant activity of platelets is not measured [17] 17. Most available in vitro 
PFTs using citrate-anticoagulated blood do not assess the contribution of thrombin generated 
by activated platelets, despite the recognition that thrombin is the key mediator of venous 
thrombus formation [18] 18. It was thus essential to compare the effect of NOACs using non-
citrated blood. 
Enhanced platelet reactivity and pro-coagulant state are not the sole determinants of lasting 
arterial occlusion in patients with ischemic stroke. Spontaneous endogenous thrombolysis is 
an important defence mechanism against tissue damage from lasting vessel occlusion [5,19-
21] 5,19-21. In patients with acute stroke, spontaneous arterial recanalization was observed in 
17-24% of patients [22-24] 22-24, and was strongly related to improved functional outcomes 
[23] 23. In 185 patients with stroke, ex vivo endogenous thrombolysis was significantly 
impaired, compared to normal volunteers [25] 25. A recent review article highlighted the 
importance of endogenous fibrinolysis in determining clinical outcome, concluding that global 
assays, assessing proaggregatory and fibrinolytic pathways, could aid in identifying impaired 
fibrinolysis as a potential target for pharmacological modulation [5] 5. The biological 
assessment of thrombotic risk should therefore not only include assessment of platelet 
function, but also endogenous thrombolytic status. The Global Thrombosis Test (GTT) 
(Thromboquest Ltd., London, UK), assesses platelet reactivity, coagulation (thrombin 
generation) and spontaneous endogenous thrombolysis from a native (non-anticoagulated) 
blood sample. In this test, thrombin generation from shear-activated platelets and fibrin-
stabilization of the initial platelet aggregates play a major role in determining the measured 
occlusion time. Therefore, it was highly suited to assess the relative and absolute effects of 
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NOACs and warfarin on overall thrombotic status. Our aim was to assess the comparative 
effect of NOACs and warfarin using an ex-vivo test of thrombosis and thrombolysis.   
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Methods 
Study design and population 
The study was approved by the local research ethics committee. Eighty patients with newly 
diagnosed, haemodynamically stable NVAF were enrolled in a single-centre, prospective 
observational study after obtaining written informed consent, each taking one of 4 
anticoagulant regimens. Patients were either naive to oral anticoagulation or had been 
previously anticoagulated with warfarin or NOAC, but had temporarily discontinued this (for 
more than 4 weeks). Exclusion criteria were as follows; less than 18 years of age, active sepsis 
or infective illness within the last month, known active malignancy, bleeding diathesis, 
anticoagulation at the time of initial sampling, need for combined antiplatelet and 
anticoagulant therapy, blood dyscrasia (platelets <100 x 109/L, haemoglobin <80 g/L, 
international normalized ratio >1.4, activated partial thromboplastin time more than twice 
the upper limit of normal, leukocyte count <3.5 x 109/L, neutrophil count <1 x 109/L), and 
alcohol consumption above recommended safe levels (i.e. more than 21 units per week for 
males, or more than 14 units per week for females) due to the potential effects of high alcohol 
levels on platelet reactivity. Baseline demographics and clinical characteristics were obtained 
from the patients and from review of case notes and electronic records. Compliance with 
NOACs was considered adequate if the pill compliance was ≥80% for at least two consecutive 
weeks prior to repeat sampling.  
Anticoagulant regimens 
The choice of oral anticoagulant was decided by the clinical team looking after the patient. 
Recruited patients who received vitamin K antagonist (VKA) therapy, were given warfarin to 
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maintain the international normalised ratio (INR) at 2.5 (range 2.0–3.0), based on local 
standard of care. Patients who received a NOAC, were given one of the following drugs: 
apixaban, a twice-daily dose of 5 mg orally (or 2.5 mg twice-daily in patients with any two or 
more of the following characteristics; age ≥80 years, weight ≤60 kg, or serum creatinine level 
≥133 μmol/L); dabigatran, a twice-daily dose of 150 mg orally (or 110 mg twice-daily in 
patients aged ≥80 years or at high risk of bleeding complications); rivaroxaban, a once-daily 
dose of 20 mg orally (or 15 mg once daily in patients with creatinine clearance of 30–49 
mL/min), based on local standard of care. All patients, but in particular those receiving 
rivaroxaban were advised of the importance of taking their medication with their main meal 
to achieve high bioavailability [26] 26. Patients were advised to avoid aspirin and any other 
over the counter medications and those at risk of ulcerative gastrointestinal disease or 
bleeding could receive prophylactic treatment with proton-pump inhibitors.  
Blood sampling 
Blood samples were taken from an antecubital vein on 2 occasions: 1) baseline, and before 
initiating oral anticoagulation, and 2) after being established on stable anticoagulation for at 
least two weeks, and in the case of warfarin, once the INR was therapeutic for at least a week. 
Samples were taken approximately 3 hours after NOACs or warfarin. Fasting was not required. 
All samples were taken from an antecubital vein using an 18-G butterfly cannula, avoiding 
prolonged tourniquet time and using a 2-syringe technique, whereby the first 5 ml was used 
for standard blood tests (biochemistry, full blood count) and the second sample used for GTT 
analysis. The patient was positioned in close proximity to the GTT such that the blood sample 
was introduced into the GTT within 15 seconds of withdrawal and the automated 
measurement begun. 
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Assessment of thrombotic status 
Assessment of thrombotic status was performed using the Global Thrombosis Test (GTT, 
Thromboquest Ltd., London, UK), an automated point-of-care test that assesses both platelet 
reactivity and endogenous thrombolysis from a native, non-anticoagulated blood sample. The 
technique assesses the time taken to form an occlusive platelet thrombus (occlusion time, 
OT), and in the second phase of the test, measures the time required to dissolve the thrombus 
formed in the first phase, through endogenous thrombolysis, which thereby restores flow 
(lysis time, LT). The principle of the GTT has previously been described in detail [5,27,28] 5,27,28. 
In brief, blood is allowed to flow in a conical plastic tube through narrow gaps where fibrin-
stabilized platelet aggregates to occlude the gaps, and the instrument measures the time (d) 
between 2 consecutive blood drops by an optical sensor in the space downstream. This time 
interval increases gradually as flow slows down and at an arbitrary point (d≥15s, before 
reaching complete occlusion), the first end-point of the measurement is displayed (occlusion 
time [OT], in seconds). Restart of blood flow after occlusion is due to spontaneous 
thrombolysis, and the second end-point of the measurement is displayed (lysis time [LT], in 
seconds). The pre-set cut-off time for OT was 900 sec and for LT was 6000 sec. The intra-assay 
and inter-assay coefficients of variation (CV) were assessed by repeated sampling on 4 
subjects. 
Statistical analysis 
This is a pilot, exploratory study and patients acted as self controls, such that bias or 
confounders were minimised. Samples of 20 patients per group were felt to be sufficient to 
give representative results when evaluating self-controls. [29,30] 29,30.  
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Data are presented as mean and standard deviation (when data normally distributed) or 
median and inter-quartile range [IQR] (non-normally distributed). Where necessary, log 
transformations were employed. Dichotomous variables were compared using chi-square 
test or Fisher’s exact test, as appropriate. The Kruskal–Wallis one-way analysis of variance 
was used to assess the differences in OT and LT between the groups and in response to 
different anticoagulants. Analyses were performed with Stata version 11.2 (StataCorp, 
College Station, TX, USA), blinded to drug allocation.  
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Results 
The characteristics of our study population are shown in Table 1. In our hands the intra-assay 
CV was OT=10% and for LT=6% and the inter-assay CV was OT=8% and for LT=9%. Distribution 
of OT, prior to anticoagulation, is shown in Figure 1. There was no significant difference in 
baseline OT between groups assigned to different oral anticoagulants (OACs) (Table 1), and 
any subtle difference was likely to be due to subtle differences in clinical characteristics 
between the groups as well as the play of chance. Compared to baseline, OT was significantly 
prolonged (showing reduced platelet reactivity) by all OACs (apixaban 403±102s vs. 496±125s, 
p=0.006; dabigatran 471±106s vs. 656±165s, p<0.00001; rivaroxaban 381±119s vs. 579±158, 
p<0.00001; warfarin 420±145s vs. 604±124s, p<0.00001) [Figure 2]. Apixaban caused 
relatively less prolongation of OT from baseline than the other NOACs or warfarin (change in 
OT with apixaban 94±135s, dabigatran 185±149s, rivaroxaban 199±104s, warfarin 184±149s; 
p=0.062). 
Distribution of LT, prior to anticoagulation, is shown in Figure 1. There was no difference in 
baseline LT between groups (Table 1). Compared to baseline, LT was reduced (showing 
enhanced endogenous thrombolysis) after oral anticoagulation compared to baseline LT 
[Figure 1 C and D, and Figure 3]. Whilst the median values of LT before and after OACs are 
numerically similar, the different sum ranks result in a significant p value (1755[1386-2314]s 
vs. 1753[807-2246]s; p=0.026, sum ranks 1987 and 1093). The LT graphs (Figure 1 C and D) 
demonstrate a significant shift in distribution. This was due predominantly to apixaban, which 
significantly reduced LT from baseline (1895[1702-2167]s vs. 1435[347-1990]s; p=0.006) 
compared to a non-significant difference in LT observed with other NOACs or warfarin 
(dabigatran 1594[1226-2069]s vs. 1539[561-2316]s, p=0.499; rivaroxaban 2085[1366-2428]s 
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vs. 1885[724-2420]s, p=0.295; warfarin 1490[1206-1960]s vs. 1776[1545-2334], p=0.601) 
[Figure 3]. 
All the variables in Table 1 were interrogated for effects on baseline OT or LT using parametric 
and non-parametric tests, as appropriate, and showed no significant relationship. Patients in 
the dabigatran group were younger than in other groups, and patients in the rivaroxaban 
group had higher CHA2DS2-VASc score than in other groups, otherwise groups were well 
matched. 
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Discussion 
All the oral anticoagulants studied reduced platelet reactivity, although apixaban caused 
relatively little effect. All NOACs, but not warfarin, exhibited a trend towards enhancing 
endogenous thrombolytic status, although this was significant only for apixaban. This raises 
the possibility of using NOACs to enhance impaired endogenous fibrinolysis in patients at high 
thrombotic risk.	
The main limitation of our study is predominantly the small sample size, and therefore the 
potential impact of small differences between groups confounding the results. Patients in the 
dabigatran group were younger than in other groups. In addition, the GTT is designed to 
measure global thrombotic status of blood subjected to high flow state (i.e. arterial 
thrombosis), so it may not provide a reliable assessment of low flow prothrombotic state, such 
as that which occurs in the left atrium of patients with AF. Although only apixaban caused 
significant reduction in LT, a trend in LT reduction was observed with the other NOACs and 
perhaps if the sample size had been sufficiently large, an effect on LT with the other oral 
anticoagulants may have been observed. Oral food intake is known to affect the absorption 
of rivaroxaban [26] 26, but since this was not monitored, we cannot be sure that maximal peak 
levels of the active metabolite had been reached at the time of sampling. Finally, we did not 
monitor the pharmacokinetics of the NOACs to ensure maximum bioavailability at the time of 
sampling, and variation in this may have influenced the results. The pharmacodynamics of 
NOACs are relatively similar, in contrast to their pharmacokinetics, which are largely specific 
to each individual agent [31] 31. As the GTT does not use any chemical reagents (such as 
platelet agonists) and the physical characteristics of the individual cartridges (and hence flow 
and shear rates) are identical, reliability and reproducibility of the test depends entirely on 
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how the blood sample is obtained. Untrained phlebotomy, prolonged venous stasis, or 
deviation from the protocol described by the manufacturer could result in variable test results. 
Our blood samples were obtained by clinicians well-versed in the technique, who took care to 
avoid prolonged tourniquet time. The patient was seated next to the GTT instrument so that 
blood could be immediately introduced into the instrument. Whilst this may be regarded by 
some as a limitation of the GTT, we feel it also makes the assessment far more physiological. 
The GTT is particularly well-adapted to investigate the role of thrombin inhibitors such as 
NOACs, for many reasons, primarily because the OT in the GTT can assess the contribution of 
thrombin [32] 32. Most conventional platelet function tests which require blood to be 
collected into citrate-anticoagulant, reduce calcium levels such that there is inhibition of 
thrombin generation from activated platelets and the important procoagulant activity of 
platelets is not measured. This is not the case with the GTT, where, thrombin generation from 
shear-activated platelets and fibrin-stabilization of the initial platelet aggregates play a major 
role in determining the measured occlusion time. Secondly, the GTT is, to our knowledge, the 
only available technique to allow assessment of fibrinolysis of a platelet-rich thrombus, under 
high shear conditions, that reflect those in an atherosclerotic arterial milieu, which was the 
aim of our study. However, the GTT cannot currently be recommended for influencing clinical 
decision making, as further evidence is needed from studies showing that decision making 
based on GTT results can favourably influence outcomes. 
Unlike VKAs, NOACs have been designed to inhibit specific single targets in the coagulation 
cascade. Apixaban and rivaroxaban are selective inhibitors of factor X (factor Xa) and do not 
require a cofactor (such as anti-thrombin) for their activity. Dabigatran is a direct competitive 
inhibitor of thrombin, the final effector in blood coagulation. These agents have no direct 
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effect on platelet aggregation, but indirectly inhibit platelet aggregation induced by thrombin. 
Our study shows that all oral anticoagulants prolong OT (showing reduction in platelet 
reactivity). Apixaban was associated with relatively less prolongation of OT than other oral 
anticoagulants and importantly, was the only anticoagulant regimen that significantly 
reduced LT (showing enhanced endogenous thrombolysis). Importantly, we did not observe 
a clear difference in effect between thrombin (dabigatran) or factor Xa (rivaroxaban and 
apixaban) inhibitors, since the effects of dabigatran and rivaroxaban were similar on OT and 
LT. We would have expected the effects of rivaroxaban and apixaban to be similar. The 
bioavailability of rivaroxaban is increased if taken with food, unlike the case with apixaban 
which is relatively independent of food-intake [26] 26. Possible insufficient food intake with 
rivaroxaban may have led to a reduced observed effect of this drug on thrombotic 
parameters, compared to apixaban. It is also possible, that there is no difference between 
NOACs, and observed differences with apixaban compared to other NOACs is simply due to 
chance, or due to differences in baseline characteristics between groups. These could include 
the relatively high frequency of diabetics and the slightly lower BMI in the apixaban group, 
the latter may have subtly influenced pharmacokinetics and pharmacodynamics, although 
this is unlikely given that no grossly obese individuals were included. Finally, compliance was 
assessed by pill-count, but since we did not measure drug concentrations, compliance and 
absorption cannot be confirmed and may have contributed to differing results between 
groups. The relatively small increase in OT with apixaban compared to other oral 
anticoagulants may indeed explain the observed lower incidence of major bleeding in large 
trials with this agent [7,33-35] 7,33-35. 
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The effect of medications on endogenous fibrinolysis has hitherto been unimpressive. Prior 
work has shown that aspirin at low doses does not alter LT, whereas more potent antiplatelet 
agents such as clopidogrel have a modest effect on LT [36] 36. Previously, in a study of patients 
with coronary disease, treatment with the PAR-1 inhibitor vorapaxar, in addition to standard 
care with antiplatelet therapy, favourably reduced LT [37] 37. Our current work lends further 
support to the notion that agents that inhibit thrombin, but not antiplatelet agents, can exert 
a favourable effect on endogenous thrombolysis. The observed favourable effect of apixaban 
on endogenous thrombolysis compared to other NOACs in our study is not fully understood. 
This finding however supports the antithrombotic properties of apixaban and can help to 
better understand the mechanism(s) of action of this drug.  
There has been a call for “personalised” antithrombotic treatment, to tailor medications to 
the individual, to optimise outcomes and reduce unwanted complications [38,39] 38,39. Large 
clinical trials are warranted to assess whether assessment of thrombotic status is useful, in 
addition to clinical risk scores, to not only predict stroke risk, but also assess response to oral 
anticoagulant therapy. Whether patients with prolonged LT derive greater advantage from 
NOACs compared to VKAs, or whether they derive potentially greater benefit from a 
particular NOAC, such as apixaban, remains to be seen. Our early, provocative data calls for 
further large studies to assess the clinical usefulness of measuring the response to oral 
anticoagulants, and how this correlates with observed effects of OACs on ex vivo tests of 
thrombosis.   
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Table 1: Baseline Patient Characteristics 
 
 
Overall 
Group    
(n = 80) 
Apixaban 
(n = 20) 
Dabigatran 
(n = 20) 
Rivaroxaban 
(n = 20) 
Warfarin 
(n = 20) 
p 
Value 
Age, yrs 72±12 72±10 65±11 78±9 74±15 0.006 
Male 49 (61) 13 (65) 15 (75) 10 (50) 11 (55) 0.375 
Body mass index  29.4±11.3 27.4±8.0 30.0±19.6 29.4±7.0 29.2±4.2 0.998 
Atrial Fibrillation 
      
     Persistent 49 (61) 12 (60) 15 (75) 9 (45) 13 (65) 0.267 
     Paroxysmal 31 (39) 8 (40) 5 (25) 11 (55) 7 (35) 0.267 
CHA2DS2-VASc score 2.9±1.7 2.9±1.8 2.1±1.6 3.7±1.7 3.0±1.5 0.030 
HAS-BLED score 1.6±1.1 1.3±0.7 1.6±0.9 2.3±1.5 1.5±1.2 0.352 
Smoking 11 (14) 4 (20) 5 (25) 1 (5) 1 (5) 0.397 
Prior CAD 20 (25) 4 (20) 4 (20) 6 (30) 6 (30) 0.468 
Diabetes mellitus 10 (13) 5 (25) 3 (15) 1 (5) 1 (5) 0.170 
Hypertension 49 (61) 12 (60) 11 (55) 13 (65) 13 (65) 0.901 
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Chronic kidney disease 
(eGFR<60) 
1 (1) 0 0 0 1 (5) 0.801 
Concomitant medications * 
      
     Beta-blocker 27 (34) 9 (45) 4 (20) 9 (45) 5 (25) 0.424 
     Calcium antagonist 22 (28) 6 (30) 6 (30) 5 (25) 5 (25) 0.657 
     ACE inhibitor 17 (21) 8 (40) 7 (35) 6 (30) 4 (20) 0.675 
     Statin 21 (26) 5 (25) 6 (30) 5 (25) 5 (25) 0.740 
     Digoxin 5 (6) 2 (10) 1 (5) 1 (5) 1 (5) 0.948 
     Proton pump inhibitor 6 (7) 2 (10) 1 (5) 1 (5) 2 (10) 0.828 
Blood tests on initial sampling 
      
     Haemoglobin (g/L) 137 ± 16 138 ± 16 141 ± 13 133 ± 17 134 ± 18 0.315 
     Haematocrit (%) 41±5 42±5 43±4 39±5 40±6 0.099 
     Platelet count (x 109/L) 215±63 220±62 217±33 209±80 214±71 0.960 
     Creatinine (µmol/L) 87±28 82±18 87±14 92±24 87±46 0.738 
     Fibrinogen (g/L) 4.4±1.6 3.6±1.0 4.8±1.9 4.6±1.6 4.6±1.4 0.076 
Baseline OT (mean±SD) 419±122s 403±102s 471±106s 381±119s 420±145s 0.111 
Baseline LT (median/IQR) 1755[1386-
2314]s 
1895[1702-
2167]s 
1594[1226-
2069]s 
2085[1366-
2428]s 
1490[1206-
1960]s 
0.103 
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Values are mean (standard deviation) or n (%). 
CAD: coronary artery disease; for explanation of CHA2DS2-VASc risk scoring in AF and HAS-BLED 
bleeding risk score please see reference [40] 40; eGFR: estimated glomerular filtration rate (The 
Modification of Diet in Renal Disease [MDRD] formula). 
* No patients were taking concomitant antiplatelet medications. 
Normal values: haemoglobin 130-180 g/L in adult males and 115-165 g/L in adult females; haematocrit 
40-52 % in adult males and 36-47 % in adult females; platelet count 150-400 x 109/L; creatinine 60-
110 μmol/L in adult males and 45-90 μmol/L in adult females; fibrinogen 2-4 g/L. 
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Figure 1: Distribution of OT and LT before and after oral anticoagulants 
(A) Baseline OT, and before initiating oral anticoagulation, (B) OT after being established on 
stable oral anticoagulants, (C) Baseline LT, and before initiating oral anticoagulation, and (D) 
LT after being established on oral anticoagulant. In NVAF patients receiving oral 
anticoagulants, OT was significantly prolonged (showing reduced platelet reactivity) 
compared to baseline OT, as evidenced by a rightward shift (higher OT, representing reduced 
platelet reactivity). In NVAF patients, LT was significantly reduced (showing enhanced 
endogenous thrombolysis) after oral anticoagulants compared to baseline LT, as evidenced 
by a leftward shift (lower LT, representing faster lysis). 
 (A)      (B)   
 
 (C)      (D)  
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Figure 2: OT at baseline and after oral anticoagulants  
The OT was significantly prolonged (less thrombotic) in patients who had been established on 
anticoagulation. The relative prolongation of OT from baseline was less with apixaban than 
with other NOACs or warfarin. Baseline OT is indicated by open bars; OT after anticoagulation 
is indicated by solid bars. *p < 0.01, †p < 0.0001. 
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Figure 3: LT at baseline and after oral anticoagulants 
Apixaban significantly reduced LT from baseline, but no significant difference in LT was 
observed with other NOACs or warfarin. Baseline LT is indicated by open bars; LT after 
anticoagulation is indicated by solid bars. *p < 0.01. 
 
 
 
